Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria tetanus pertussis vaccine + hepatitis B vaccine + haemophilus influenzae type b vaccine
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The **diphtheria tetanus pertussis vaccine + hepatitis B vaccine + haemophilus influenzae type b vaccine** (DTP-HBV-Hib) is a pentavalent combination vaccine designed for primary immunization in infants to prevent diphtheria, tetanus, pertussis (whooping cough), hepatitis B, and invasive *Haemophilus influenzae* type b (Hib) infections such as meningitis and pneumonia. It contains diphtheria toxoid, tetanus toxoid, whole-cell pertussis antigens (or acellular in some formulations), hepatitis B surface antigen, and Hib polysaccharide conjugate, administered intramuscularly to induce protective antibodies against these pathogens. Studies show comparable immunogenicity to separate vaccines for most components, though potentially lower responses for Hib and tetanus, with increased local reactions; it reduces injection visits and improves compliance in routine childhood schedules.[1][2]
- Brand names
- QuintavaxPentavacPentacelEasyfive-TTQuinvaxemComvac 5Comvac5Comvac-5PentashieldShan 5Shan5Shan-5Pentabio
- Other names
- DTP-HBV-Hib vaccinepentavalent vaccine
02
Targets
HBsAg (Hepatitis B surface antigen)TT (Tetanus toxoid)
Beyond the preview
Go deeper on diphtheria tetanus pertussis vaccine + hepatitis B vaccine + haemophilus influenzae type b vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria tetanus pertussis vaccine + hepatitis B vaccine + haemophilus influenzae type b vaccine.